Kenneth Bender, PharmD, MA

ADA 2019-Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.

Four studies presented at PAINWeek 2016 review the success of abuse-deterrent opioid formulations in stemming abuse and non-medical use.